• Saskia Van der Meer, Boudewijn J Kollen, Willem H Hirdes, Martijn G Steffens, Josette E H M Hoekstra-Weebers, Rien M Nijman, and Marco H Blanker.
• Department of Urology, Isala Clinics, Zwolle, the Netherlands.
• BJU Int. 2013 Jul 1; 112 (1): 26-31.

ObjectiveTo determine the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) publication in 2009 on prostate-specific antigen (PSA) level testing by Dutch general practitioners (GPs) in men aged ≥40 years.Materials And MethodsRetrospective study with a Dutch insurance company database (containing PSA test claims) and a large district hospital-laboratory database (containing PSA-test results). The difference in primary PSA-testing rate as well as follow-up testing before and after the ERSPC was tested using the chi-square test with statistical significance at P < 0.05.ResultsDecline in PSA tests 4 months after ERSPC publication, especially for men aged ≥60 years. Primary testing as well as follow-up testing decreased, both for PSA levels of <4 ng/mL as well as for PSA levels of 4-10 ng/mL. Follow-up testing after a PSA level result of >10 ng/mL moderately increased (P = 0.171). Referral to a urologist after a PSA level result of >4 ng/mL decreased slightly after the ERSPC publication (P = 0.044).ConclusionsAfter the ERSPC publication primary PSA testing as well as follow-up testing decreased. Follow-up testing seemed not to be adequate after an abnormal PSA result. The reasons for this remain unclear.© 2013 BJU International.

31 keywords...

hide…